Skip to content
2000
Volume 21, Issue 2
  • ISSN: 1573-4021
  • E-ISSN: 1875-6506

Abstract

Hypertension, commonly known as high blood pressure, is a chronic condition characterized by elevated arterial pressure. It occupies a unique position in population health. It is the leading cause of cardiovascular disease and the most common non-communicable condition affecting millions worldwide and is a major public health challenge.

The etiology of hypertension involves a complex interplay of environmental and pathophysiological factors alongside genetics, diet, lifestyle, and other coexisting medical conditions. Treatment typically involves medication and lifestyle adjustments such as dietary changes, regular exercise, weight management, and stress reduction to pharmacological interventions involving drugs like diuretics, beta-blockers & ACE inhibitors to lower blood pressure. The pathogenesis of hypertension is linked to endothelial dysfunction, vascular remodelling, sympathetic nervous system activation, and the renin-angiotensin-aldosterone system. Diagnosis is made by measuring blood pressure using a sphygmomanometer, with stages including prehypertension, stage 1 hypertension, and stage 2 hypertension. Effective management of hypertension requires lifestyle modifications such as dietary changes, regular exercise, weight control, and reduced alcohol consumption, alongside pharmacological interventions. As hypertension continues to be a leading cause of death and disability globally, understanding and addressing these factors are crucial for mitigating the widespread impact of hypertension on public health.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/chyr/10.2174/0115734021349254250224074832
2025-03-06
2025-09-25

  • From This Site

    /content/journals/chyr/10.2174/0115734021349254250224074832
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. CDC - High blood pressure.2024Available from: https://www.cdc.gov/bloodpressure/about.htm
  2. OparilS. AcelajadoM.C. BakrisG.L. Hypertension.Nat. Rev. Dis. Primers2018411801410.1038/nrdp.2018.14 29565029
     [Google Scholar]
  3. McEnieryC.M. CockcroftJ.R. RomanM.J. FranklinS.S. WilkinsonI.B. Central blood pressure: Current evidence and clinical importance.Eur. Heart J.201435261719172510.1093/eurheartj/eht565 24459197
     [Google Scholar]
  4. LinS.R. LinS.Y. ChenC.C. FuY.S. WengC.F. Exploring a new natural treating agent for primary hypertension: Recent findings and forthcoming perspectives.J. Clin. Med.2019811200310.3390/jcm8112003 31744165
     [Google Scholar]
  5. High blood pressure (hypertension).Available from: https://www.mayoclinic.org/diseases-conditions/high-blood-pressure/symptoms-causes/syc-20373410
  6. WHO - HypertensionAvailable from: https://www.who.int/news-room/fact-sheets/detail/hypertension
  7. Understanding blood pressure readings.Available from: https://www.heart.org/en/health-topics/high-blood-pressure/understanding-blood-pressure-readings
  8. GroverS. AnandT. KishoreJ. Hypertension and its correlates among pregnant women consuming tobacco in India: Findings from the national family health survey-4.Prev. Med. Rep.20233510228110.1016/j.pmedr.2023.102281 37576846
     [Google Scholar]
  9. Health threats from high blood pressure.Available from: https://www.heart.org/en/health-topics/high-blood-pressure/health-threats-from-high-blood-pressure
  10. ForouzanfarM.H. AfshinA. AlexanderL.T. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: A systematic analysis for the global burden of disease study 2015.Lancet2016388100531659172410.1016/S0140‑6736(16)31679‑8 27733284
     [Google Scholar]
  11. Invisible numbers: The true extent of non-communicable diseases and what to do about them. Geneva: World Health Organization2022https://www.who.int/publications/i/item/9789240057661
  12. GuptaR. XavierD. Hypertension: The most important non communicable disease risk factor in India.Indian Heart J.2018704565572
     [Google Scholar]
  13. National family health survey (NFHS-5), 2019-21: India.2022Available from: https://ruralindiaonline.org/en/library/resource/national-family-health-survey-nfhs-5-2019-21-india
  14. GuptaR. GaurK. AhujaS. AnjanaR.M. Recent studies on hypertension prevalence and control in India 2023.Hypertens. Res.20244761445145610.1038/s41440‑024‑01585‑y 38379011
     [Google Scholar]
  15. GeldsetzerP. Diabetes and hypertension in India: A nationally representative study of 1.3 million adults.JAMA Int. Med.20181783363372
     [Google Scholar]
  16. ChenS. Essential hypertension.J. Hypertens.2012301424510.1097/HJH.0b013e32834ee23c 22157586
     [Google Scholar]
  17. GoA.S. BaumanM.A. KingC.S.M. An effective approach to high blood pressure control: A science advisory from the american heart association, the american college of cardiology, and the centers for disease control and prevention.Hypertension201463487888510.1161/HYP.0000000000000003 24243703
     [Google Scholar]
  18. HegdeS. AhmedI. AeddulaN.R. Secondary hypertension. Stat Pearls.Treasure Island, FLStat Pearls Publishing2024
     [Google Scholar]
  19. BeeversG. LipG.Y. O’BrienE. ABC of hypertension: The pathophysiology of hypertension.BMJ2001322729191291610.1136/bmj.322.7291.912 11302910
     [Google Scholar]
  20. VincentJ.L. Understanding cardiac output.Crit. Care200812417410.1186/cc6975 18771592
     [Google Scholar]
  21. SharmaR. SharmaS. Physiology, blood volume. Stat Pearls.Treasure Island, FLStat Pearls Publishing2024
     [Google Scholar]
  22. Nanoparticle-based therapies in hypertension.Available from: https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.123.19523
  23. Pathophysiology of hypertension.Available from: https://en.wikipedia.org/wiki/Pathophysiology_of_hypertension
  24. PattenR.D. KonstamM.A. Ventricular remodeling and the renin angiotensin aldosterone system.Congest. Heart Fail.20006418719210.1111/j.1527‑5299.2000.80159.x 12147951
     [Google Scholar]
  25. RobertM. Physiology and regulation of the renin–angiotensin–aldosterone system. Textbook of Nephro-EndocrinologyAcademic Press2009147165
     [Google Scholar]
  26. DrożdżD. DrożdżM. WójcikM. Endothelial dysfunction as a factor leading to arterial hypertension.Pediatr. Nephrol.20233892973298510.1007/s00467‑022‑05802‑z 36409370
     [Google Scholar]
  27. ZhouM.S. WangA. YuH. Link between insulin resistance and hypertension: What is the evidence from evolutionary biology?Diabetol. Metab. Syndr.2014611210.1186/1758‑5996‑6‑12 24485020
     [Google Scholar]
  28. SalvettiA. BrogiG. LeggeD.V. BerniniG.P. The inter-relationship between insulin resistance and hypertension.Drugs199346S214915910.2165/00003495‑199300462‑00024 7512468
     [Google Scholar]
  29. Circulation research.Available from: https://www.ahajournals.org/doi/epub/10.1161/CIRCRESAHA.121.318082
  30. WheltonP.K. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A report of the american college of Cardiology/American heart association task force on clinical practice guidelines.Hypertension2018716e13e115
     [Google Scholar]
  31. OjangbaT. BoamahS. MiaoY. Comprehensive effects of lifestyle reform, adherence, and related factors on hypertension control: A review.J. Clin. Hypertens.202325650952010.1111/jch.14653 37161520
     [Google Scholar]
  32. Types of blood pressure medications.Available from: https://www.heart.org/en/health-topics/high-blood-pressure/changes-you-can-make-to-manage-high-blood-pressure/types-of-blood-pressure-medications
  33. Medline plus trusted health information for youAvailable from: https://medlineplus.gov/howtopreventhighbloodpressure.html
  34. CDC - Centers for disease control and prevention.Available from: https://www.cdc.gov/bloodpressure/prevent.htm
  35. SacksF.M. SvetkeyL.P. VollmerW.M. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet.N. Engl. J. Med.2001344131010.1056/NEJM200101043440101 11136953
     [Google Scholar]
  36. LevitanE.B. WolkA. MittlemanM.A. Relation of consistency with the dietary approaches to stop hypertension diet and incidence of heart failure in men aged 45 to 79 years.Am. J. Cardiol.2009104101416142010.1016/j.amjcard.2009.06.061 19892061
     [Google Scholar]
  37. NathensonP. The DASH diet.Nursing2017474575910.1097/01.NURSE.0000512500.35560.b7 28328778
     [Google Scholar]
  38. d’AlmeidaS.M.K. SpillereR.S. ZuchinaliP. SouzaC.G. Mediterranean diet and other dietary patterns in primary prevention of heart failure and changes in cardiac function markers: A systematic review.Nutrients20181015810.3390/nu10010058 29320401
     [Google Scholar]
  39. UtsugiT.M. OhkuboT. KikuyaM. High fruit intake is associated with a lower risk of future hypertension determined by home blood pressure measurement: The OHASAMA study.J. Human Hypert.201125316417110.1038/jhh.2010.48
     [Google Scholar]
  40. WoodE. HeinS. HeissC. WilliamsC. Rodriguez-MateosA. Blueberries and cardiovascular disease prevention.Food Funct.201910127621763310.1039/C9FO02291K
     [Google Scholar]
  41. Food data central food details.2018Available from: https://fdc.nal.usda.gov/fdc-app.html#/food-details/173944/nutrients
  42. BenjamimC.J.R. PortoA.A. ValentiV.E. Nitrate derived from beetroot juice lowers blood pressure in patients with arterial hypertension: A systematic review and meta-analysis.Front. Nutr.2022982303910.3389/fnut.2022.823039
     [Google Scholar]
  43. Are there health benefits from chocolate?2019Available from: https://www.heart.org/en/news/2019/02/12/are-there-health-benefits-from-chocolate
  44. Get started with exercise to lower blood pressure.Available from: https://www.webmd.com/hypertension-high-blood-pressure/ss/slideshow-lowering-bp-tips
  45. RajP. NancyA. ThandapillyS.J. YuL. NetticadanT. The effects of oat ingredients on blood pressure in spontaneously hypertensive rats.J. Food Biochem.20204410e1340210.1111/jfbc.13402
     [Google Scholar]
  46. RiedK. Garlic lowers blood pressure in hypertensive subjects, improves arterial stiffness and gut microbiota: A review and meta-analysis.Exp. Ther. Med.202019214721478
     [Google Scholar]
  47. 10 Foods that help lower blood pressure naturally.Available from: https://www.ncoa.org/article/10-foods-that-help-lower-blood-pressure-naturally
  48. The 17 Best foods for high blood pressure.Available from: https://www.healthline.com/nutrition/foods-high-blood-pressure#fatty-fish
  49. IoannidisJ.P.A. Diagnosis and treatment of hypertension in the 2017 ACC/AHA guidelines and in the real world.JAMA2018319211511610.1001/jama.2017.19672 29242891
     [Google Scholar]
  50. JordanJ. KurschatC. ReuterH. Arterial hypertension.Dtsch. Arztebl. Int.201811533-34557568 30189978
     [Google Scholar]
  51. High blood pressure.Available from: https://www.nhs.uk/conditions/high-blood-pressure-hypertension/treatment/
  52. CareyR.M. MoranA.E. WheltonP.K. Treatment of hypertension.JAMA2022328181849186110.1001/jama.2022.19590 36346411
     [Google Scholar]
  53. KhalilH. ZeltserR. Antihypertensive medications. Stat Pearls.Treasure Island, FLStat Pearls Publishing2023
     [Google Scholar]
  54. YetisginA.A. CetinelS. ZuvinM. KosarA. KutluO. Therapeutic nanoparticles and their targeted delivery applications.Molecules2020259219310.3390/molecules25092193 32397080
     [Google Scholar]
  55. DateA.A. HanesJ. EnsignL.M. Nanoparticles for oral delivery: Design, evaluation and state-of-the-art.J. Control. Release201624050452610.1016/j.jconrel.2016.06.016 27292178
     [Google Scholar]
  56. SmithB.R. GambhirS.S. Nanomaterials for in vivo imaging.Chem. Rev.2017117390198610.1021/acs.chemrev.6b00073 28045253
     [Google Scholar]
  57. SmithB.R. EdelmanE.R. Nanomedicines for cardiovascular disease.Nat. Cardiovasc. Res.20232435136710.1038/s44161‑023‑00232‑y 39195953
     [Google Scholar]
  58. CareyR.M. PadiaS.H. Angiotensin AT2 receptors: Control of renal sodium excretion and blood pressure.Trends Endocrinol. Metab.2008193848710.1016/j.tem.2008.01.003 18294862
     [Google Scholar]
  59. AlamT. KhanS. GabaB. HaiderM.F. BabootaS. AliJ. Nanocarriers as treatment modalities for hypertension.Drug Deliv.201724135836910.1080/10717544.2016.1255999 28165823
     [Google Scholar]
  60. PaulisL. UngerT. Novel therapeutic targets for hypertension.Nat. Rev. Cardiol.20107843144110.1038/nrcardio.2010.85 20567239
     [Google Scholar]
  61. PaulisL. RajkovicovaR. SimkoF. New developments in the pharmacological treatment of hypertension: Dead-end or a glimmer at the horizon?Curr. Hypertens. Rep.20151764210.1007/s11906‑015‑0557‑x 25893478
     [Google Scholar]
  62. NunesT. RochaJ.F. Vaz-da-SilvaM. Safety, tolerability, and pharmacokinetics of etamicastat, a novel dopamine-β-hydroxylase inhibitor, in a rising multiple-dose study in young healthy subjects.Drugs R D.201010422524210.2165/11586310‑000000000‑00000 21171669
     [Google Scholar]
  63. NiazT. ShabbirS. ManzoorS. Antihypertensive nano-ceuticales based on chitosan biopolymer: Physico-chemical evaluation and release kinetics.Carbohydr. Polym.201614226827410.1016/j.carbpol.2016.01.047 26917399
     [Google Scholar]
  64. OparilS. SchmiederR.E. New approaches in the treatment of hypertension.Circ. Res.201511661074109510.1161/CIRCRESAHA.116.303603 25767291
     [Google Scholar]
  65. MorrellN.W. ArcherS.L. DeFeliceA. Anticipated classes of new medications and molecular targets for pulmonary arterial hypertension.Pulm. Circ.20133122624410.4103/2045‑8932.109940 23662201
     [Google Scholar]
  66. MüllerR.H. MäderK. GohlaS. Solid lipid nanoparticles (SLN) for controlled drug delivery - A review of the state of the art.Eur. J. Pharm. Biopharm.200050116117710.1016/S0939‑6411(00)00087‑4 10840199
     [Google Scholar]
  67. NolteA. SchneiderM. WalkerT. Gene-silencing for treatment of cardiovascular diseases. Regenerative medicine and tissue engineering - cells and biomaterials.Rijeka, CroatiaINTECH201110.5772/10659
     [Google Scholar]
  68. IglarzM. BinkertC. MorrisonK. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist.J. Pharmacol. Exp. Ther.2008327373674510.1124/jpet.108.142976 18780830
     [Google Scholar]
  69. O’DriscollC.M. GriffinB.T. Biopharmaceutical challenges associated with drugs with low aqueous solubility—The potential impact of lipid-based formulations.Adv. Drug Deliv. Rev.200860661762410.1016/j.addr.2007.10.012 18155800
     [Google Scholar]
  70. Palatin technologies, Inc.Available from: http://www.palatin.com/programs/heart-failure
  71. PridgenE.M. AlexisF. FarokhzadO.C. Polymeric nanoparticle technologies for oral drug delivery.Clin. Gastroenterol. Hepatol.201412101605161010.1016/j.cgh.2014.06.018 24981782
     [Google Scholar]
  72. AntalI. KubovcikovaM. ZavisovaV. Magnetic poly(d,l-lactide) nanoparticles loaded with aliskiren: A promising tool for hypertension treatment.J. Magn. Magn. Mater.201538028028410.1016/j.jmmm.2014.10.089
     [Google Scholar]
  73. RanpiseN.S. KorabuS.S. GhodakeV.N. Second generation lipid nanoparticles (NLC) as an oral drug carrier for delivery of lercanidipine hydrochloride.Colloids Surf. B Biointerfaces2014116818710.1016/j.colsurfb.2013.12.012 24445002
     [Google Scholar]
  74. MüllerR.H. RadtkeM. WissingS.A. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations.Adv. Drug Deliv. Rev.200254S1S131S15510.1016/S0169‑409X(02)00118‑7 12460720
     [Google Scholar]
  75. GiménezM.V.M. KassuhaD. ManuchaW. Nanotechnology offers a promising therapeutic approach for the treatment of hypertension.Hipertens. Riesgo Vasc.201734312012710.1016/j.hipert.2016.11.002 27986450
     [Google Scholar]
  76. TiwariG. TiwariR. BannerjeeS.K. Drug delivery systems: An updated review.Int. J. Pharm. Investig.20122121110.4103/2230‑973X.96920 23071954
     [Google Scholar]
  77. GuptaS. KesarlaR. ChotaiN. MisraA. OmriA. Systematic approach for the formulation and optimization of solid lipid nanoparticles of efavirenz by high pressure homogenization using design of experiments.BioMed Res. Int.20172017111810.1155/2017/5984014 28243600
     [Google Scholar]
  78. ShubayevV.I. PisanicT.R.II JinS. Magnetic nanoparticles for theragnostics.Adv. Drug Deliv. Rev.200961646747710.1016/j.addr.2009.03.007 19389434
     [Google Scholar]
  79. HainfeldJ.F. SlatkinD.N. SmilowitzH.M. The use of gold nanoparticles to enhance radiotherapy in mice.Phys. Med. Biol.20044918N309N31510.1088/0031‑9155/49/18/N03 15509078
     [Google Scholar]
  80. FangJ. NakamuraH. MaedaH. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect.Adv. Drug Deliv. Rev.201163313615110.1016/j.addr.2010.04.009 20441782
     [Google Scholar]
  81. JiangZ. LiJ. ChenM. ZhangZ. GaoW. ZhaiG. Enhancing the bioavailability of captopril through nanostructured lipid carriers: Preparation, characterization, and pharmacokinetic evaluation.Drug Dev. Ind. Pharm.2015415697703
     [Google Scholar]
  82. SahooS.K. ParveenS. PandaJ.J. The present and future of nanotechnology in human health care.In: Nanomedicine: Nanotechnology, Biology and Medicine. (1) Elsevier20073203110.1016/j.nano.2006.11.008
     [Google Scholar]
/content/journals/chyr/10.2174/0115734021349254250224074832
Loading
An Overview of Hypertension: Pathophysiology, Risk Factors, and Modern Management
Current Hypertension Reviews 21, 64 (2025); https://doi.org/10.2174/0115734021349254250224074832
/content/journals/chyr/10.2174/0115734021349254250224074832
/content/journals/chyr/10.2174/0115734021349254250224074832
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): Cardiovascular disease; lifestyle modifications; non-communicable condition; pathophysiology; pharmacological interventions; public health

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test